• contact

هنك أبحاث كثيرة كتبت في هذا الموضوع، سنحاول هنا وضع بعضها.للاستفسار يرجى الاتصال على العنوان التالي:

info@bnhas.org

 

 
 

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

 
 

الزيارات : 56

التاريخ : 22-06-2010

 
 

عن الملف :

المرفقات : لا يوجد

 
 

 

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up.

Am J Hematol. 2010 Jun;85(6):403-8.

Abstract

A randomized, controlled clinical trial established the efficacy and safety of short-term use of hydroxyurea in adult sickle cell anemia. To examine the risks and benefits of long-term hydroxyurea usage, patients in this trial were followed for 17.5 years during which they could start or stop hydroxyurea. The purpose of this follow-up was to search for adverse outcomes and estimate mortality. For each outcome and for mortality, exact 95% confidence intervals were calculated, or tests were conducted at alpha = 0.05 level (P-value <0.05 for statistical significance). Although the death rate in the overall study cohort was high (43.1%; 4.4 per 100 person-years), mortality was reduced in individuals with long-term exposure to hydroxyurea. Survival curves demonstrated a significant reduction in deaths with long-term exposure. Twenty-four percent of deaths were due to pulmonary complications; 87.1% occurred in patients who never took hydroxyurea or took it for <5 years. Stroke, organ dysfunction, infection, and malignancy were similar in all groups. Our results, while no longer the product of a randomized study because of the ethical concerns of withholding an efficacious treatment, suggest that long-term use of hydroxyurea is safe and might decrease mortality. 2010 Wiley-Liss, Inc.

PMID: 20513116 [PubMed - indexed for MEDLINE]PMCID: PMC2879711 [Available on 2011/6/1]

 
     
 

Archive

Title Date Visits

 Levels of pain control

28-09-2011 216

 Public Awareness of Glucose-6- Phosphate Dehydrogenase ( G6PD) Dificiency

11-08-2011 221

 fact about alpha thalassemia

10-08-2011 236

 Prevalence of Abnormal Hemoglobins among Students in Bahrain: A Ten-Year Study

09-03-2011 68

 Beta Thalassemia Frequency in Bahrain: A Ten Year Study

27-09-2010 63

 Public awareness of sickle cell disease in Bahrain

23-09-2010 53

 Premarital genetic counselling A new law in the kingdom of bahrain

23-09-2010 54

 links of several reserch published on Bahrain Medical Bulletin Journal

31-08-2010 57

 The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

22-06-2010 56

 Frequency of G6PD Deficiency among Bahraini students: A Ten Years Study

01-03-2010 52

الصفحات :1-2-3

الارشيف

العنوان التاريخ الزيارات
 

Public Awareness of Beta Thalassemia in Bahrain

05-04-2012 55
 

THE CHANGING PROFILE OF CONSANGUINITY

01-02-2012 58
 

Levels of pain control

28-09-2011 55
 

The Campaign to control genetic blood diseases in Bahrain.

09-03-2011 66
 

Prevalence of Abnormal Hemoglobins among Students in Bahrain: A Ten-Year Study

09-03-2011 56
 

Beta Thalassemia Frequency in Bahrain: A Ten Year Study

27-09-2010 53
 

Premarital genetic counselling A new law in the kingdom of bahrain

09-03-2011 61
 

Public awareness of sickle cell disease in bahrain

09-03-2011 88
 

روابط لأبحاث مختلفة من مجلة البحرين الطبية

07-07-2010 58
 

Frequency of G6PD Deficiency among Bahraini students: A Ten Years Study

07-07-2010 55

الصفحات :1-2-3-4